Detalles de la búsqueda
1.
Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial.
Cardiovasc Diabetol
; 22(1): 330, 2023 11 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38017482
2.
Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial.
Diabetes Obes Metab
; 24(10): 1950-1956, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35635326
3.
Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial.
Diabetes Obes Metab
; 25(5): 1413-1418, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36655422
4.
Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A Post Hoc Analysis of CREDENCE Trial.
Kidney Int Rep
; 9(2): 347-355, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38344715
5.
Dapagliflozin and Anemia in Patients with Chronic Kidney Disease.
NEJM Evid
; 2(6): EVIDoa2300049, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38320128
6.
Membranous Nephropathy-Like Apolipoprotein E Deposition Disease with Apolipoprotein E Toyonaka and Homozygous Apolipoprotein E2/2 without Dyslipidemia, with Characteristic Electron-Dense Deposits.
Case Rep Nephrol Dial
; 12(2): 96-104, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35950048
7.
Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS.
Diabetes Care
; 45(11): 2644-2652, 2022 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36134918
8.
Clinical and Pathological Significance of Autoantibodies to Erythropoietin Receptor in Type 2 Diabetic Patients With CKD.
Kidney Int Rep
; 3(1): 133-141, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-29340323
Resultados
1 -
8
de 8
1
Próxima >
>>